Inclusion Criteria:  Severe mitral regurgitation≥3+ (moderate or above degenerative mitral regurgitation disease, or with stenosis is included); Age≥70 years; or patients who are 60~70 years old, and the STS risk score indicate that participants are at high risk of traditional surgery or cannot tolerate traditional thoracotomy;  4) Left ventricular ejection fraction≥30%； 5) As assessed by multidisciplinary cardiac team (at least two cardiac surgeons/one cardiologist), patients who are at extremely high-risk or unsuitable for routine mitral valve surgery with evaluation; 6) Patients who understand the purpose of the trial and volunteer to participate in, sign the informed consent form and are willing to accept relevant examinations and clinical follow-ups.  Anatomy selection Criteria：  The regurgitant jet of mitral valve originates from the A2 and P2 (the lesions of A2/P2 in mitral valve causes regurgitation); The width of the mitral valve prolapsed area is ≤15mm, Height of Prolapse ≤10mm or coaptation depth≤11mm, coaptation height≥2mm, effective length of anterior and posterior leaflets>1cm (conforming to EVEREST II recommended mitral valve interventional edge-to-edge repair standards); Effective mitral valve orifice area≥ 4.0cm2; No obvious calcification of the mitral valve annulus and valve leaflets; Patient's anatomical conditions allow transseptal approach.  Exclusion Criteria:  Previous cardiac mitral valve surgery; Patients with Infective endocarditis or having an active infection; Patients with mitral regurgitation caused by pure mitral stenosis; Combined with untreated severe coronary artery disease Pulmonary hypertension (pulmonary artery systolic pressure>70mmHg); Patients with severe right heart failure; Patients are extremely weak and cannot tolerate general anesthesia or are in shock that circulatory support is needed; Patients with hypertrophic cardiomyopathy, restrictive cardiomyopathy, and constrictive pericarditis; Patients receiving chronic dialysis; Patients with clear coagulation dysfunction and severe coagulopathy; Patients with clear contraindications to anticoagulant drugs; Patients with stroke or transient ischemic attack within 30 days; Echocardiography found any intracardiac mass, left ventricle or atrial thrombus; Patients who require surgery or interventional therapy for other valvular lesions; Patients with severe macrovascular lesions requiring surgical treatment; Patients' imaging examinations suggest that the anatomy of the heart and valves are inappropriate;